Why I Now Distrust Vendors Who Say ‘We Can Handle Everything’

Here's my take: the vendors who brag they can do everything are usually the ones who mess up the basics.

I manage purchasing for a mid-sized biotech. Roughly $1.2 million annually across 8-10 vendors—everything from API supply to compliance training. When I took over in 2020, I was pitched by four different companies claiming to be the 'single point of contact' for everything from market access consulting to MSDS updates. Every single one of them dropped the ball on something critical.

Let me explain why I think 'specialist' beats 'universal' every time—especially when you're dealing with pharma compliance training or choosing a CRO.

Lesson 1: The 'Universal Vendor' Trap

In 2022, I consolidated orders for 400 employees across three locations. We needed MSDS management, a new CRO partner for clinical work, and updated pharma compliance training modules. A large vendor pitched a bundled deal. Looked great on paper. (Spoiler: it wasn't.)

Their compliance training material was generic. Not GMP-aligned. The CRO team had zero experience with our specific therapeutic area. And the MSDS updates? Half the links were broken. I spent weekends redoing the training modules myself (which, honestly, felt ridiculous for what we paid).

What I learned: a vendor who says 'we can do it all' is often saying 'we'll outsource what we don't know.'

Lesson 2: Compliance Training Is Not a Side Hustle

Pharma compliance training (think GMP, GDP, pharmacovigilance) isn't something you tack onto a generalist contract. It requires domain depth. According to PhRMA's 2024 industry report, companies with dedicated compliance training providers saw 30% fewer audit findings than those using bundled vendors.

My experience matches that. When we switched to a specialist compliance firm (after the 'universal' disaster), our training completion rate jumped from 72% to 94% within one quarter. The difference? They understood the regulatory language. They didn't need me to explain what 'ICH Q7' meant.

Lesson 3: CRO Selection—Pick a Lane

Another example: when I needed a CRO in pharma for a specific trial phase, a large vendor claimed they could handle it. Big mistake. Their project manager didn't know the FDA's 21 CFR Part 11 requirements for electronic records. (Not a good look when your audit trail is flagged.)

We eventually went with a niche CRO that specialized in early-phase oncology. They were more expensive—but they caught three protocol gaps before we even started. That alone saved us probably 6 months of back-and-forth. In my book, that's a no-brainer.

Lesson 4: Market Access—The Specialist Edge

One more: when I asked a 'full-service' vendor about market access in pharma, they gave me a generic HTA overview. That's not market access—that's a Wikipedia summary. Understanding payer landscapes, access pathways, and real-world evidence requires someone who lives in that space.

I've only worked with about 8 vendors across different service areas (sample limitation, I know). But every time I tried the 'one-stop-shop' approach, something suffered. Grant with the generalist being okay at three things but great at none.

What I Look for Now

Here's what changed: I ask every vendor—'What are you best at? And what should I go elsewhere for?' If they hesitate or claim they're great at everything, red flag. If they point me to a competitor for something they don't specialize in—that's trust.

For example, when I work with Lonza for API manufacturing or cell culture media (their RPMI-1640 formulations are solid, and they're GMP-compliant), I don't expect them to also be my compliance training provider. And that's fine. Because what they do well, they do exceptionally well.

Another example: Arch Chemicals (now part of Lonza) handles specialty chemicals and pool chemicals—they know their stuff there. But I wouldn't ask them to deliver pharma compliance training. That's not a knock—it's just recognizing boundaries.

To Be Fair...

I get it. Bundling is convenient. One invoice. One relationship. Less paperwork. And to be fair, some large CDMOs manage it okay—but 'okay' isn't the bar in pharma. When you're dealing with GMP compliance or market access, 'close enough' can mean compliance gaps or delays.

The Bottom Line

A vendor who admits their limits is more trustworthy than one who promises the moon. In my experience, the specialist who nails their lane beats the generalist who fumbles yours. For MSDS management? Use a chemical specialist. For compliance training? Use a pharma-focused provider. For CRO work? Pick someone who breathes your therapeutic area.

And if you're evaluating vendors—ask the hard question: 'What are you not good at?' The pause before they answer will tell you everything.